Get the Stockscreener App
0.2949
2.19%
-0.0066
After Hours:
.29
-0.0049
-1.66%
Glycomimetics Inc stock is traded at $0.2949, with a volume of 1.11M.
It is down -2.19% in the last 24 hours and up +12.17% over the past month.
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
See More
Previous Close:
$0.3015
Open:
$0.282
24h Volume:
1.11M
Relative Volume:
0.71
Market Cap:
$19.03M
Revenue:
$1.16M
Net Income/Loss:
$-39.74M
P/E Ratio:
-0.4756
EPS:
-0.62
Net Cash Flow:
$-35.02M
1W Performance:
+1.69%
1M Performance:
+12.17%
6M Performance:
+59.41%
1Y Performance:
-90.14%
1-Day Range:
$0.281
$0.3099
1-Week Range:
$0.2539
$0.37
52-Week Range:
$0.1406
$3.18
Glycomimetics Inc Stock (GLYC) Company Profile
Name
Glycomimetics Inc
Sector
Industry
Phone
240-243-1201
Address
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare GLYC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLYC
Glycomimetics Inc
|
0.2949 | 19.03M | 1.16M | -39.74M | -35.02M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Glycomimetics Inc Stock (GLYC) Latest News
US Penny Stocks To Watch In February 2025 - Yahoo Finance
GlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Update - Defense World
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week - NewsBreak
GlycoMimetics adjusts merger terms with Crescent Biopharma - MSN
GlycoMimetics And GENFIT Announce Significant Agreement Amendments - Evrim Ağacı
GlycoMimetics adjusts merger terms with Crescent Biopharma By Investing.com - Investing.com UK
GLYCOMIMETICS INC SEC 10-K Report - TradingView
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World
Glycomimetics, Inc. Announces Cessation of Brian Hahn as Chief Financial Officer, No Later Than March 31, 2025 - Marketscreener.com
Glycomimetics, Inc. Announces Cessation of Harout Semerjian as Chief Executive Officer, No Later Than March 31, 2025 - Marketscreener.com
Reviewing PureTech Health (NASDAQ:PRTC) and GlycoMimetics (NASDAQ:GLYC) - Defense World
StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics executives to depart amid merger plans By Investing.com - Investing.com South Africa
GlycoMimetics executives to depart amid merger plans - MSN
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? - MSN
GlycoMimetics and Crescent Biopharma Update Investor Presentation in Connection with Proposed Merger - Defense World
GlycoMimetics and Crescent Biopharma Announce Merger Plans - Yahoo Finance
Avacta Appoints Brian Hahn as Chief Financial Officer - The Manila Times
Avacta Appoints Brian Hahn as Chief Financial Officer - GlobeNewswire Inc.
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics (NASDAQ:GLYC) Earns Sell Rating from Analysts at StockNews.com - Defense World
Is It Time For Me To Buy GlycoMimetics Inc (NASDAQ: GLYC) Stock Now? - Stocks Register
GlycoMimetics Receives Extension Notice from Nasdaq Regarding Minimum Bid Price ComplianceOn December 19, 2024, GlycoMimetics, Inc. (NASDAQ: GLYC) disclosed in an 8-K filing with the Securities and Exchange Commission that it had received an e - Defense World
GlycoMimetics, Inc. announced that it expects to receive $200 million in funding - Marketscreener.com
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
GlycoMimetics skyrockets on buyout deal - MSN
Logos Global Management LP Acquires 5 Million Shares in GlycoMim - GuruFocus.com
GlycoMimetics: Q3 Earnings Snapshot - Darien Times
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - Quantisnow
Crescent Biopharma to Showcase Cancer Drug Pipeline at Jefferies Healthcare Conference - StockTitan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, PFIE, GLYC on Behalf of Shareholders - The Malaysian Reserve
Finansavisen - Finansavisen
RA Capital Management's Strategic Acquisition of GlycoMimetics I - GuruFocus.com
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - BioSpace
Top 3 Penny Stocks to Watch Today – October 31, 2024 - The Global Domains News
Shares of Biotech Company Up Over 100% Premarket Following Merger & Funding Announcement - MSN
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYC - WICZ
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALTR, PFIE, GLYC on Behalf of Shareholders - Marketscreener.com
What Do Wall Street Analysts Think About GlycoMimetics Inc (NASDAQ: GLYC) Stock? - Stocks Register
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc.GLYC - PR Newswire
Glycomimetics Inc Stock (GLYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):